Our results showed that a blockade of IL-6 signaling by anti-IL-6/IL-6R/JAK antibodies plus SOC significantly reduced the mortality rate but did not increase the risk of secondary infections compared to SOC alone in patients with COVID-19. This evidence concerns the gene IL6R and infection.